Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
From Denmark to Japan, the UK, France, and Sweden, physicist Ken Andersen has worked at neutron sources around the world. With significant contributions to neutron scattering and the scientific community, he’s now serving in his most important role yet.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
The ExOne Company, the global leader in industrial sand and metal 3D printers using binder jetting technology, announced it has reached a commercial license agreement with Oak Ridge National Laboratory to 3D print parts in aluminum-infiltrated boron carbide.
Marcel Demarteau is director of the Physics Division at the Department of Energy’s Oak Ridge National Laboratory. For topics from nuclear structure to astrophysics, he shapes ORNL’s physics research agenda.
A multi-institutional team, led by a group of investigators at Oak Ridge National Laboratory, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease. The feat has earned the team a finalist nomination for the Association of Computing Machinery, or ACM, Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
NellOne Therapeutics has licensed a drug delivery system from the Department of Energy’s Oak Ridge National Laboratory that is designed to transport therapeutics directly to cells infected by SARS-CoV-2, the virus causing COVID-19.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.